FY2025 Earnings Estimate for Imunon Issued By HC Wainwright

Imunon, Inc. (NASDAQ:IMNN) – Equities researchers at HC Wainwright issued their FY2025 EPS estimates for Imunon in a report issued on Thursday, February 5th. HC Wainwright analyst E. Bodnar expects that the company will post earnings of ($2.64) per share for the year. The consensus estimate for Imunon’s current full-year earnings is ($1.68) per share. HC Wainwright also issued estimates for Imunon’s Q4 2025 earnings at ($1.22) EPS, Q1 2026 earnings at ($1.29) EPS, Q2 2026 earnings at ($0.98) EPS, Q3 2026 earnings at ($1.08) EPS, Q4 2026 earnings at ($1.01) EPS, FY2026 earnings at ($4.27) EPS, FY2027 earnings at ($2.20) EPS, FY2028 earnings at ($3.11) EPS and FY2029 earnings at ($1.95) EPS.

A number of other equities analysts also recently commented on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Imunon in a report on Thursday, January 22nd. Brookline Capital Acquisition restated a “buy” rating on shares of Imunon in a report on Wednesday, January 7th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $232.50.

Imunon Stock Performance

NASDAQ IMNN opened at $3.27 on Monday. The stock has a market cap of $10.04 million, a P/E ratio of -0.34 and a beta of 2.14. Imunon has a fifty-two week low of $2.99 and a fifty-two week high of $41.22. The stock has a 50 day simple moving average of $3.67 and a two-hundred day simple moving average of $4.84.

Imunon (NASDAQ:IMNN) last posted its earnings results on Thursday, November 13th. The company reported ($1.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.73) by $0.57.

Hedge Funds Weigh In On Imunon

An institutional investor recently raised its position in Imunon stock. Riverview Capital Advisers LLC raised its position in shares of Imunon, Inc. (NASDAQ:IMNN) by 193.3% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 34,364 shares of the company’s stock after purchasing an additional 22,649 shares during the quarter. Riverview Capital Advisers LLC owned 1.41% of Imunon worth $176,000 at the end of the most recent quarter. 4.47% of the stock is owned by institutional investors.

Key Headlines Impacting Imunon

Here are the key news stories impacting Imunon this week:

• Positive Sentiment: Imunon announced a streamlining of operations to concentrate resources on its OVATION 3 program — a sign management is prioritizing its lead asset and cutting noncore spend, which can reduce cash burn and improve runway if executed. IMNN: Streamlining Operations to Focus on OVATION 3
• Neutral Sentiment: AmericanBankingNews published an item summarizing HC Wainwright’s ongoing model updates (including longer‑term forecasts). The piece appears to be informational about analyst coverage rather than new company disclosures, so its immediate market impact is likely limited unless it reveals new model changes. What is HC Wainwright’s Estimate for Imunon FY2030 Earnings?
• Negative Sentiment: HC Wainwright published a suite of quarterly and multi‑year EPS forecasts that project continued losses through FY2029 (and high FY2026 losses). Key forecast highlights from analyst E. Bodnar: Q1–Q4 2026 estimates show steep quarterly losses (e.g., Q1 2026 -$1.29; Q2 -$0.98; Q3 -$1.08; Q4 -$1.01) and FY2026 at -$4.27 EPS; FY2027 -$2.20; FY2028 -$3.11; FY2029 -$1.95. Those sizable multi‑year loss projections increase the risk of further dilution, financing needs, and downward pressure on the share price unless clinical progress or funding news changes the outlook. MarketBeat: IMNN analyst notes

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.